Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data

V. Sandecká, L. Pour, I. Špička, J. Minařík, J. Radocha, T. Jelínek, A. Heindorfer, P. Pavlíček, M. Sýkora, A. Jungová, P. Kessler, M. Wróbel, D. Starostka, J. Ullrychová, L. Stejskal, M. Štork, J. Straub, T. Pika, L. Brožová, S. Ševčíková, V....

. 2021 ; 107 (4) : 466-474. [pub] 20210728

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012133

OBJECTIVES: This study compared the use of bortezomib in different combination regimens in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible. PATIENTS AND METHODS: We analyzed data from the Registry of Monoclonal Gammopathies (RMG) of the Czech Myeloma Group (CMG) to provide real-world evidence of outcome for 794 newly diagnosed MM transplant ineligible patients. The most frequently used regimen was VCd (bortezomib-cyclophosphamide-dexamethasone) (47.5%) over VMP (bortezomib-melphalan-prednisone) (21.7%), BDd (bortezomib-doxorubicin-dexamethasone) (9.8%), and VTd (bortezomib-thalidomide-dexamethasone) (2.9%). RESULTS: The overall response rate (ORR) was 69.2% (478/691), including 12.6% (≥ CR); 34.7% very good partial responses (VGPR); and 21.9% partial responses (PR). Among triplet regimens, VMP was the most effective regimen compared to VCd, BDd, and VTd. Median PFS was 22.3 vs. 18.5 vs. 13.7 vs. 13.8 mo, (P = .275), respectively, and median OS was 49 vs. 41.7 vs. 37.9 vs. 32.2 mo (P = .004), respectively. The most common grade 3-4 toxicities were anemia in 17.4% and infections in 18% of patients. CONCLUSION: Our study confirmed that bortezomib-based treatment is effective and safe in NDMM transplant ineligible patients, especially VMP, which was identified as superior between bortezomib-based induction regimens not only in clinical trials, but also in real clinical practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012133
003      
CZ-PrNML
005      
20230714085129.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ejh.13683 $2 doi
035    __
$a (PubMed)34272773
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Sandecká, Viera $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic $1 https://orcid.org/0000000340748497
245    10
$a Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data / $c V. Sandecká, L. Pour, I. Špička, J. Minařík, J. Radocha, T. Jelínek, A. Heindorfer, P. Pavlíček, M. Sýkora, A. Jungová, P. Kessler, M. Wróbel, D. Starostka, J. Ullrychová, L. Stejskal, M. Štork, J. Straub, T. Pika, L. Brožová, S. Ševčíková, V. Maisnar, R. Hájek
520    9_
$a OBJECTIVES: This study compared the use of bortezomib in different combination regimens in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible. PATIENTS AND METHODS: We analyzed data from the Registry of Monoclonal Gammopathies (RMG) of the Czech Myeloma Group (CMG) to provide real-world evidence of outcome for 794 newly diagnosed MM transplant ineligible patients. The most frequently used regimen was VCd (bortezomib-cyclophosphamide-dexamethasone) (47.5%) over VMP (bortezomib-melphalan-prednisone) (21.7%), BDd (bortezomib-doxorubicin-dexamethasone) (9.8%), and VTd (bortezomib-thalidomide-dexamethasone) (2.9%). RESULTS: The overall response rate (ORR) was 69.2% (478/691), including 12.6% (≥ CR); 34.7% very good partial responses (VGPR); and 21.9% partial responses (PR). Among triplet regimens, VMP was the most effective regimen compared to VCd, BDd, and VTd. Median PFS was 22.3 vs. 18.5 vs. 13.7 vs. 13.8 mo, (P = .275), respectively, and median OS was 49 vs. 41.7 vs. 37.9 vs. 32.2 mo (P = .004), respectively. The most common grade 3-4 toxicities were anemia in 17.4% and infections in 18% of patients. CONCLUSION: Our study confirmed that bortezomib-based treatment is effective and safe in NDMM transplant ineligible patients, especially VMP, which was identified as superior between bortezomib-based induction regimens not only in clinical trials, but also in real clinical practice.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a bortezomib $x terapeutické užití $7 D000069286
650    _2
$a cyklofosfamid $x terapeutické užití $7 D003520
650    _2
$a dexamethason $x terapeutické užití $7 D003907
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a doxorubicin $x terapeutické užití $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melfalan $x terapeutické užití $7 D008558
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x diagnóza $x farmakoterapie $x mortalita $x patologie $7 D009101
650    _2
$a prednison $x terapeutické užití $7 D011241
650    12
$a registrace $7 D012042
650    _2
$a thalidomid $x terapeutické užití $7 D013792
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pour, Luděk $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic
700    1_
$a Špička, Ivan $u 1st Department of Medicine, Department of Hematology, Charles University and General Hospital, Prague, Czech Republic
700    1_
$a Minařík, Jiří $u Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic $1 https://orcid.org/000000030513326X
700    1_
$a Radocha, Jakub $u 4th Department of Internal Medicine, Hematology, University Hospital and Charles University in Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Jelínek, Tomáš $u Department of Hematooncology, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Heindorfer, Adriana $u Department of Clinical Hematology, Hospital Liberec, Czech Republic
700    1_
$a Pavlíček, Petr $u Department of Internal Medicine and Hematology, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
700    1_
$a Sýkora, Michal $u Department of Clinical Hematology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic
700    1_
$a Jungová, Alexandra $u Hematology and Oncology Department, Charles University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Kessler, Petr $u Department of Hematology and Transfusion Medicine, Hospital Pelhrimov, Czech Republic
700    1_
$a Wróbel, Marek $u Department of Clinical Hematology, Hospital Novy Jicin, Czech Republic $7 xx0303976
700    1_
$a Starostka, David $u Department of Clinical Hematology, Hospital Havirov, Czech Republic
700    1_
$a Ullrychová, Jana $u Department of Clinical Hematology, Regional Health Corporation, Masaryk Hospital, Usti nad Labem, Czech Republic
700    1_
$a Stejskal, Lukáš $u Department of Hematology, Silesian Hospital in Opava, Opava, Czech Republic
700    1_
$a Štork, Martin $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic $1 https://orcid.org/0000000270728537
700    1_
$a Straub, Jan $u 1st Department of Medicine, Department of Hematology, Charles University and General Hospital, Prague, Czech Republic
700    1_
$a Pika, Tomáš $u Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Brožová, Lucie $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
700    1_
$a Ševčíková, Sabina $u Babak Myeloma Group, Department of Pathophysiology, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000271946771
700    1_
$a Maisnar, Vladimír $u 4th Department of Internal Medicine, Hematology, University Hospital and Charles University in Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Hájek, Roman $u Department of Hematooncology, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000169556267 $7 nlk20000083645
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 107, č. 4 (2021), s. 466-474
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34272773 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20230714085129 $b ABA008
999    __
$a ok $b bmc $g 1789637 $s 1163334
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 107 $c 4 $d 466-474 $e 20210728 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace